Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on Mar 01, 2017 11:47am
203 Views
Post# 25912554

RE:RE:RE:RE:Great post from Tada ...

RE:RE:RE:RE:Great post from Tada ...

GV:  I think there is a potential calculation to be made here.   If someone can come up with a reliable estimate of the ratio between 5 point MACE events and 3 point MACE events, then you can roughly convert the 129 first events into 3 point MACE events.   After that, you'd need to come up with a way to estimate the number that might be eliminated through the adjudication process.  I would think that that might be a low number for 3 point MACE events but would be larger for 5 point MACE events, since there is more judgment involved in 5 point MACE determinations (hence it is less favored and seen as less reliable).

The above would get one to a rough estimate I think of where we are at reletive to the 125 events needed for the futility analysis.   

My guess is that the August estimate is the estimate for when the analysis will be released.  They will probably reach 125 before that and then will need some time to calculate the information.

Since they are hinting that they might be able to get there sooner than August, I would venture a guess that we are getting closer to those 125 events than we might otherwise have guessed.

Bullboard Posts